About The Study
The objective of this study was to evaluate the immune response of three different seasonal influenza (Fluviral®) vaccine dosing strategies in HIV infected adults.
Researchers assessed which strategies worked best in producing an adequate immune response to the vaccine as measured by an antibody blood test.
Study Approach
Study participants were randomized into one of three groups:
- Group A: single standard dose injection of Fluviral
- Group B: standard dose injection of Fluviral followed 28 days later by a booster standard dose of Fluviral
- Group C: a double dose of Fluviral followed 28 days later by a second double dose of Fluviral.
All injections were given in the upper arm muscle. Groups A and B were compared to was Group C.
Study population
A total of 298 (90 per cent male, 98 percent on HAART) participants were recruited from 12 sites across Canada. Eligible participants were HIV-positive adults aged 18–60 years prior to the 2008–2009 influenza season. Of the enrolled participants, 84% had received the flu vaccine the previous year.
Results
Researchers measured serum hemagglutinin inhibition (HI) activity — the effectiveness of the vaccine to prevent influenza infection. Two hundred and ninety-seven participants received at least one injection. The primary outcome was a doubling of antibodies relative to baseline (start of study) at week 8, comparing groups A to C and B to C.
Over the 20-week period of assessment, 32 influenza-like illnesses (ILI) were reported, of these, six influenza infections were confirmed. ILI and positive infection results were evenly distributed between groups A, B and C. All dosing strategies were well tolerated. None of 8 serious adverse effects (SAEs) were immunization-related.
Conclusion
Double dose and booster dose Fluviral is well tolerated in HIV. Booster dosing or increased dosing may improve seroprotection in patients with low baseline SP levels to circulating influenza strains such as pandemic H1N1.
Background
Viverra varius diam risus urna quam vivamus. Tempor lorem neque, orci eget tincidunt condimentum fringilla. Et convallis et magna enim nullam magna sit dictum iaculis. Malesuada potenti faucibus lacus placerat pulvinar augue tempus placerat bibendum. Blandit felis nunc porta enim lectus sem. Sed at habitant convallis facilisis viverra. Non volutpat, elementum nisi phasellus pharetra fusce.
Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.
Study Approach
Study participants were randomized into one of three groups:
Group A: single standard dose injection of Fluviral
Group B: standard dose injection of Fluviral followed 28 days later by a booster standard dose of Fluviral
Group C: a double dose of Fluviral followed 28 days later by a second double dose of Fluviral.
All injections were given in the upper arm muscle. Groups A and B were compared to was Group C.
Study population
A total of 298 (90 per cent male, 98 percent on HAART) participants were recruited from 12 sites across Canada. Eligible participants were HIV-positive adults aged 18″60 years prior to the 2008″2009 influenza season. Of the enrolled participants, 84% had received the flu vaccine the previous year.
Investigators
Here’s who is leading this study.
Can’t find what you’re looking for?
Email ctninfo@ctnplus.ca.
